Dulaglutide: difference between revisions
Diff·revision 7 → 8·09:56, 30 Dec 2024
Difference between revision 7 and revision 8 of Dulaglutide. 6 lines changed; the page grew by 761 bytes.
| Revision 7 — 01:05, 11 Dec 2024 MolarMassMaeve (talk) state plainly that the research-use-only form is not approved for human use 3,106 bytes ±0 | Revision 8 — 09:56, 30 Dec 2024 ArchiveBot (talk) bot: repair redlinked category 3,867 bytes +761 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Dulaglutide | 2 | | name = Dulaglutide |
| + | 3 | | subtitle = Clinical data | |
| 3 | | INN = dulaglutide | 4 | | INN = dulaglutide |
| 4 | | Class = [[GLP-1 receptor agonist]] | 5 | | Class = [[GLP-1 receptor agonist]] |
| ⋮ | ⋮ | ||
| 23 | 24 | ||
| 24 | Against it: subcutaneous bioavailability is lower — roughly half, compared with about 89% for [[Semaglutide|semaglutide]] — because a 60 kDa protein reaches the circulation largely by lymphatic drainage rather than by capillary absorption. Anti-drug antibodies are detectable in a small percentage of recipients, though neutralising antibodies are rare and clinically significant loss of effect has not been demonstrated.{{r|glaesner2010}} | 25 | Against it: subcutaneous bioavailability is lower — roughly half, compared with about 89% for [[Semaglutide|semaglutide]] — because a 60 kDa protein reaches the circulation largely by lymphatic drainage rather than by capillary absorption. Anti-drug antibodies are detectable in a small percentage of recipients, though neutralising antibodies are rare and clinically significant loss of effect has not been demonstrated.{{r|glaesner2010}} |
| + | 26 | ||
| + | 27 | == Clinical evidence == | |
| + | 28 | Across the AWARD programme, dulaglutide 0.75–4.5 mg weekly reduced glycated haemoglobin by roughly 0.8–1.6 percentage points depending on dose and background therapy, with weight change of about −1 to −4.7 kg.{{r|gerstein2019}} | |
| + | 29 | ||
| + | 30 | The REWIND trial randomised 9,901 people with type 2 diabetes, most of whom did not have established cardiovascular disease, and reported a hazard ratio of 0.88 (95% CI 0.79–0.99) for the primary cardiovascular composite over a median 5.4 years. Its distinctive feature is the predominantly primary-prevention population, which differentiates it from the outcome trials of other agents in the class and makes its result harder to compare with them.{{r|gerstein2019}} | |
| 25 | 31 | ||
| 26 | == References == | 32 | == References == |